Bridging clinical insight and laboratory model in high-grade serous ovarian carcinoma (HGSOC) using DNA sequencing-based profiling of TP53

ABSTRACT

The most prevalent and aggressive subtype of epithelial ovarian cancer is high grade serous ovarian carcinoma (HGSOC) which is characterized by late-stage diagnosis and poor prognosis, and it accounts for approximately 70% of all ovarian cancer cases. The OVCAR3 cell line serves as a valuable in vitro model for studying the molecular mechanisms underlying the disease. In this study the Sanger sequencing method was used to detect DNA sequences, specifically the TP53 gene, making it ideal for comparing clinical and laboratory data. In this study, drug repurposing agents metformin, chlorpromazine (CPZ) alone, and a combination of the two, were tested on both clinical and laboratory ovarian cancer samples to evaluate hemocytometer and clonogenic assays for dead cells and proliferation, respectively. Following drug treatment, both samples were further analyzed using Sanger sequencing to detect TP53 profiling. The resulting data were analyzed to achieve successfully-known target regions and worked as a bridge between clinical and laboratory models. The insights gained from this study not only validate OVCAR3 as a representative model for HGSOC, but also provide a foundation for developing targeted therapeutic strategies.